Alnylam director Marsha H. Fanucci resigns; Peter N. Kellogg named Audit Chair

ALNYLAM PHARMACEUTICALS, INC.

Marsha H. Fanucci resigned from Board effective Sept 29, 2023; no disagreement with company.
Peter N. Kellogg appointed Chair of Audit Committee; qualifies as audit committee financial expert.
Board size reduced from 13 to 12 members effective upon Fanucci's resignation.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Marsha H. Fanucci

Director

ALNY · ALNYLAM PHARMACEUTICALS, INC.

Effective: 2023-09-29
Filed: September 28, 2023, 7:59 PM ET

On September 26, 2023, Marsha H. Fanucci informed the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”) of her resignation from the Board effective as of September 29, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Marsha H. Fanucci resigned as Director at ALNYLAM PHARMACEUTICALS, INC..

Action: resigned
Role: Director

Exact text from the filing

On September 26, 2023, Marsha H. Fanucci informed the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”) of her resignation from the Board effective as of September 29, 2023.

View on SEC.gov

ALNYLAM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-245768

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.